Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ACLY | P53396 | 6/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 1/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201453 | 0.89 | KEAP1 (0.56) | CYP2C9CYP2C19ACLYMCL1KEAP1 | |
| SCHEMBL7316092 | 0.86 | CYP2C9 (0.68) | CYP2C9CYP2C19ACLYMCL1KEAP1 | |
| SCHEMBL23200342 | 0.86 | MEN1 (0.66) | KEAP1NFE2L2FFAR4METAP2SLC16A3 | |
| SCHEMBL23200290 | 0.84 | CYP2C9 (0.76) | CYP2C9CYP2C19ACLYMCL1FFAR4 | |
| SCHEMBL12201452 | 0.80 | ACLY (0.74) | CYP2C9CYP2C19ACLYMCL1METAP2 | |
| SCHEMBL12200777 | 0.80 | FFAR4 (0.64) | ACLYKEAP1NFE2L2FFAR4METAP2 | |
| SCHEMBL9402850 | 0.79 | MCL1 (0.67) | CYP2C9CYP2C19ACLYMCL1METAP2 | |
| SCHEMBL7318557 | 0.78 | ACLY (0.54) | CYP2C9CYP2C19ACLYMCL1METAP2 | |
| SCHEMBL9997061 | 0.78 | MCL1 (0.67) | MCL1KEAP1NFE2L2PGR | |
| SCHEMBL3988508 | 0.78 | METAP2 (0.74) | CYP2C9MCL1KEAP1NFE2L2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385820-B1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | CYP2C9 1109/4885CYP2C19 2213/4885ACLY 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.